Pulmatrix, Inc. (PULM)Healthcare | Biotechnology | Framingham, United States | NasdaqCM
1.41 USD
+0.06
(4.833%)
⇧
(April 21, 2026, 11:04 a.m.
EDT)
Short-term: ★★☆☆☆ | Long-term: ☆☆☆☆☆ | Dividends: ☆☆☆☆☆ |
Hot Take | April 18, 2026, 11:32 p.m. EDT
PULM is a high-risk speculative trade with a strong short-term downside downside signal predicted by its forecasting model (-19.5% over 45 days), driven by severe earnings deterioration (-19% YoY EPS, negative returns) and aggressive dilution evidenced by recent reverse merger activity. There are no dividends and no long-term investment thesis due to negative cash flow and book value erosion. |
| Model | MAE |
|---|---|
| AutoTheta ✓ | 0.166380 |
| MSTL | 0.240008 |
| AutoETS | 0.252368 |
| AutoARIMA | 0.252372 |
Forecast horizon: 45 days | Selected: AutoTheta
| Forecast Reliability | |
|---|---|
| Score | 46% |
| H-stat | 6.35 |
| Ljung-Box p | 0.000 |
| Jarque-Bera p | 0.686 |
| Excess Kurtosis | -0.38 |
| Attribute | Value |
|---|---|
| Sector | Healthcare |
| Market Cap | 5,149,721 |
| Forward P/E | -0.31 |
| Beta | 1.97 |
| Website | https://www.pulmatrix.com |
| Attribute | Value |
|---|---|
| 52 Week Change | -0.7868463 |
| Address1 | 945 Concord Street |
| Address2 | Suite 1217 |
| All Time High | 4,235.0 |
| All Time Low | 1.16 |
| Ask | 1.23 |
| Ask Size | 1 |
| Average Daily Volume10 Day | 28,730 |
| Average Daily Volume3 Month | 46,513 |
| Average Volume | 46,513 |
| Average Volume10Days | 28,730 |
| Beta | 1.966 |
| Bid | 1.35 |
| Bid Size | 14 |
| Book Value | 1.043 |
| City | Framingham |
| Compensation As Of Epoch Date | 1,767,139,200 |
| Country | United States |
| Crypto Tradeable | 0 |
| Currency | USD |
| Current Price | 1.41 |
| Current Ratio | 12.55 |
| Custom Price Alert Confidence | HIGH |
| Date Short Interest | 1,774,915,200 |
| Day High | 1.46 |
| Day Low | 1.271 |
| Display Name | Pulmatrix |
| Dividend Date | 1,549,411,200 |
| Earnings Timestamp End | 1,755,259,200 |
| Earnings Timestamp Start | 1,754,909,940 |
| Ebitda | -5,063,000 |
| Ebitda Margins | 0.0 |
| Enterprise To Ebitda | -0.163 |
| Enterprise Value | 824,323 |
| Eps Forward | -4.5 |
| Eps Trailing Twelve Months | -1.41 |
| Esg Populated | 0 |
| Exchange | NCM |
| Exchange Data Delayed By | 0 |
| Exchange Timezone Name | America/New_York |
| Exchange Timezone Short Name | EDT |
| Fifty Day Average | 2.02374 |
| Fifty Day Average Change | -0.6137401 |
| Fifty Day Average Change Percent | -0.30327022 |
| Fifty Two Week Change Percent | -78.68463 |
| Fifty Two Week High | 9.37 |
| Fifty Two Week High Change | -7.96 |
| Fifty Two Week High Change Percent | -0.8495197 |
| Fifty Two Week Low | 1.16 |
| Fifty Two Week Low Change | 0.25 |
| Fifty Two Week Low Change Percent | 0.21551725 |
| Fifty Two Week Range | 1.16 - 9.37 |
| Financial Currency | USD |
| First Trade Date Milliseconds | 1,395,408,600,000 |
| Float Shares | 3,628,107 |
| Forward Eps | -4.5 |
| Forward P E | -0.31333333 |
| Free Cashflow | -3,447,625 |
| Full Exchange Name | NasdaqCM |
| Full Time Employees | 2 |
| Gmt Off Set Milliseconds | -14,400,000 |
| Gross Margins | 0.0 |
| Gross Profits | -38,000 |
| Has Pre Post Market Data | 1 |
| Held Percent Insiders | 0.0074400003 |
| Held Percent Institutions | 0.09766 |
| Implied Shares Outstanding | 3,652,285 |
| Industry | Biotechnology |
| Industry Disp | Biotechnology |
| Industry Key | biotechnology |
| Is Earnings Date Estimate | 1 |
| Language | en-US |
| Last Fiscal Year End | 1,767,139,200 |
| Last Split Date | 1,646,092,800 |
| Last Split Factor | 1:20 |
| Long Business Summary | Pulmatrix, Inc., a biopharmaceutical company, focused on development of novel inhaled therapeutic products to prevent and treat migraine and respiratory diseases with unmet medical needs in the United States. The company offers iSPERSE, an engineered dry powder delivery platform, which enables delivery of small or large molecule drugs to the lungs by inhalation for local or systemic applications. It engages in developing PUR1800, a narrow spectrum kinase inhibitor completed Phase 1b clinical trials for the treatment of acute exacerbations in chronic obstructive pulmonary disease; PUR1900 for the treatment of allergic bronchopulmonary aspergillosis in patients with asthma and cystic fibrosis; and PUR3100, an iSPERSE formulation of dihydroergotamine which is in Phase 1 for the treatment of acute migraine. It has a license agreement with RespiVert Ltd. for access to a portfolio of kinase inhibitor compounds. The company was founded in 2003 and is headquartered in Framingham, Massachusetts. |
| Long Name | Pulmatrix, Inc. |
| Market | us_market |
| Market Cap | 5,149,721 |
| Market State | REGULAR |
| Max Age | 86,400 |
| Message Board Id | finmb_26897567 |
| Most Recent Quarter | 1,767,139,200 |
| Net Income To Common | -5,162,000 |
| Next Fiscal Year End | 1,798,675,200 |
| Non Diluted Market Cap | 4,912,323 |
| Open | 1.39 |
| Operating Cashflow | -5,433,000 |
| Operating Margins | 0.0 |
| Payout Ratio | 0.0 |
| Phone | 888 355 4440 |
| Previous Close | 1.345 |
| Price Hint | 4 |
| Price To Book | 1.3518696 |
| Profit Margins | 0.0 |
| Quick Ratio | 12.426 |
| Quote Source Name | Nasdaq Real Time Price |
| Quote Type | EQUITY |
| Recommendation Key | none |
| Region | US |
| Regular Market Change | 0.06499994 |
| Regular Market Change Percent | 4.832709 |
| Regular Market Day High | 1.46 |
| Regular Market Day Low | 1.271 |
| Regular Market Day Range | 1.271 - 1.46 |
| Regular Market Open | 1.39 |
| Regular Market Previous Close | 1.345 |
| Regular Market Price | 1.41 |
| Regular Market Time | 1,776,783,841 |
| Regular Market Volume | 92,590 |
| Return On Assets | -0.45883 |
| Return On Equity | -0.80928004 |
| Sand P52 Week Change | 0.34445214 |
| Sector | Healthcare |
| Sector Disp | Healthcare |
| Sector Key | healthcare |
| Shares Outstanding | 3,652,285 |
| Shares Percent Shares Out | 0.0022 |
| Shares Short | 8,053 |
| Shares Short Previous Month Date | 1,772,150,400 |
| Shares Short Prior Month | 2,779 |
| Short Name | Pulmatrix, Inc. |
| Short Percent Of Float | 0.0022 |
| Short Ratio | 0.08 |
| Source Interval | 15 |
| State | MA |
| Symbol | PULM |
| Total Cash | 4,088,000 |
| Total Cash Per Share | 1.119 |
| Total Debt | 0 |
| Tradeable | 0 |
| Trailing Annual Dividend Rate | 0.0 |
| Trailing Annual Dividend Yield | 0.0 |
| Trailing Eps | -1.41 |
| Trailing Peg Ratio | None |
| Triggerable | 1 |
| Two Hundred Day Average | 3.828805 |
| Two Hundred Day Average Change | -2.4188051 |
| Two Hundred Day Average Change Percent | -0.6317389 |
| Type Disp | Equity |
| Volume | 92,590 |
| Website | https://www.pulmatrix.com |
| Zip | 1,701 |